Maravai LifeSciences Holdings Inc
NASDAQ:MRVI

Watchlist Manager
Maravai LifeSciences Holdings Inc Logo
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Watchlist
Price: 5.62 USD 6.24%
Market Cap: 1.4B USD
Have any thoughts about
Maravai LifeSciences Holdings Inc?
Write Note

Maravai LifeSciences Holdings Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maravai LifeSciences Holdings Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Pre-Tax Income
$617.7m
CAGR 3-Years
96%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Pre-Tax Income
$6.8B
CAGR 3-Years
-12%
CAGR 5-Years
11%
CAGR 10-Years
13%
Danaher Corp
NYSE:DHR
Pre-Tax Income
$4.1B
CAGR 3-Years
-17%
CAGR 5-Years
7%
CAGR 10-Years
2%
Mettler-Toledo International Inc
NYSE:MTD
Pre-Tax Income
$955.2m
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
8%
Agilent Technologies Inc
NYSE:A
Pre-Tax Income
$1.5B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Pre-Tax Income
$1.5B
CAGR 3-Years
17%
CAGR 5-Years
33%
CAGR 10-Years
12%
No Stocks Found

Maravai LifeSciences Holdings Inc
Glance View

Market Cap
1.4B USD
Industry
Life Sciences Tools & Services

Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 470 full-time employees. The company went IPO on 2020-11-20. The firm provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The firm's segments include Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The company also provides research products for labeling and detecting proteins in cells and tissue samples. Its products include CleanCap, messenger ribonucleic acid (mRNA) and oligonucleotide. The Biologics Safety Testing focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing spectrum. The firm provides ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets.

MRVI Intrinsic Value
3.57 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Maravai LifeSciences Holdings Inc's Pre-Tax Income?
Pre-Tax Income
617.7m USD

Based on the financial report for Dec 31, 2023, Maravai LifeSciences Holdings Inc's Pre-Tax Income amounts to 617.7m USD.

What is Maravai LifeSciences Holdings Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
96%

Over the last year, the Pre-Tax Income growth was 12%. The average annual Pre-Tax Income growth rates for Maravai LifeSciences Holdings Inc have been 96% over the past three years .

Back to Top